FDA approves first transcatheter tricuspid valve replacement system, Evoque, for severe symptomatic tricuspid regurgitation patients.

The FDA has approved the first transcatheter tricuspid valve replacement system, called the Evoque tricuspid valve replacement system. This system is designed to treat patients with severe symptomatic tricuspid regurgitation despite optimal medical therapy. The Evoque system was approved by the EU in October 2023 and represents a significant advancement in the treatment of tricuspid regurgitation, offering an alternative to high-risk surgical procedures.

February 02, 2024
12 Articles

Further Reading